Quick Answer
ADMA BIOLOGICS, INC. reported Revenue (ASC 606) of $510.17 million for fiscal year 2025.
ADMA BIOLOGICS, INC. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $510.17M | +19.6% |
| 2024 | $426.45M | +65.2% |
| 2023 | $258.21M | +67.6% |
| 2022 | $154.08M | +90.4% |
| 2021 | $80.94M | +91.7% |
| 2020 | $42.22M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $134.22M | +12.0% | +10.0% |
| June 30, 2025 | $121.98M | +13.8% | +6.3% |
| March 31, 2025 | $114.80M | +40.2% | -4.2% |
| September 30, 2024 | $119.84M | +78.1% | +11.8% |
| June 30, 2024 | $107.19M | +78.3% | +30.9% |
| March 31, 2024 | $81.88M | +43.9% | +21.7% |
| September 30, 2023 | $67.28M | +63.7% | +11.9% |
| June 30, 2023 | $60.12M | +77.3% | +5.6% |
- ADMA BIOLOGICS, INC. showed an increase of +19.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2020–2025 period, ADMA BIOLOGICS, INC.’s revenue (asc 606) has grown by 1108.4% (from $42.22 million to $510.17 million).
- The most recent figure is from ADMA BIOLOGICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: